Navigation path

Pharmaceuticals - Community Register

  

Community register of orphan medicinal products


GRANTED  

Product information

2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one

EU orphan designation number: EU/3/12/989   
Active ingredient: 2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one
Indication: Treatment of ovarian cancer
Sponsor: AstraZeneca UK Limited
Alderley Park, Macclesfield, Cheshire, SK10 4TG United Kingdom

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
30/04/2012 Orphan Designation EMA/OD/151/11 (2012)2985 of 26/04/2012
19/05/2015 Transfer of orphan designation EMA/OD/151/11/T/01 (2015)3438 of 13/05/2015